|Bid||12.93 x 800|
|Ask||12.94 x 1400|
|Day's Range||12.32 - 13.02|
|52 Week Range||5.27 - 18.50|
|Beta (3Y Monthly)||0.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.25|
Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017, reflecting ~2% YoY growth. Xifaxan and Relistor primarily contributed to the revenue growth of Salix Pharmaceuticals in the third quarter. In the third quarter, Xifaxan and Relistor witnessed ~11% and 88% YoY organic revenue growth.
On November 13, Bausch Health stock closed at $26.63, which is a ~1.60% increase from its prior close of $26.21 on November 12, 2018. On November 13, Bausch Health stock closed at $26.63, a ~92% increase from its 52-week low of $13.86 on November 15, 2017. On October 3, 2018, Bausch Health hit its 52-week high of $28.45.
This mutual fund is focused on small-cap stocks, and the fund's managers like the outlook for small caps.
The best pharmaceutical stocks to buy have a commonality: Strong Composite Ratings and Relative Strength Ratings.
On its third-quarter earnings conference call, Endo International (ENDP) raised its projection for operating expenses as a percentage of its total revenue guidance for 2018 from its previously projected range of 26.0%–27.0% to 27.0%.
On its third-quarter earnings conference call, Endo International (ENDP) raised its revenue guidance for 2018 from the previously projected range of $2.75 billion–$2.85 billion to $2.87 billion–$2.92 billion mainly due to its stronger-than-anticipated performance YTD (year-to-date).
The stock was trading 22.77% lower than its closing price of $17.08 on November 1. It closed at $13.49 on November 9, 2.27% higher than its previous closing price. Endo International reported its third-quarter earnings results on November 8.
Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.
Endo International stock crashed Thursday despite beating quarterly expectations as the generic drugmaker reportedly plans to launch its cellulite treatment in 2020.
Endo International Plc said on Thursday it expects to launch its treatment for cellulite in the second half of 2020, a day after the company announced results from two late-stage trials testing the drug. The generic drugmaker, which beat third-quarter revenue and profit estimates, has pushed into other segments of its business, such as medical aesthetics, to cushion the impact of large retail pharmacies gaining more negotiating power for generics pricing.
Endo (ENDP) delivered earnings and revenue surprises of 20.34% and 6.96%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Dublin-based company said it had a loss of 77 cents. Earnings, adjusted for amortization costs and asset impairment costs, came to 71 cents per share. The results exceeded Wall ...
Endo International PLC shares rose 6% in Thursday premarket trade after the company reported third-quarter adjusted profit and revenue beats and upbeat 2018 guidance. The company reported a net loss of $173.2 million, or a loss of 77 cents per share, after a loss of $96.7 million, or a loss of 43 cents per share in the year-earlier period. Endo said its adjusted earnings-per-share from continuing operations were 71 cents, above the FactSet consensus of 59 cents. Revenue declined to $745.5 million from $786.9 million in the year-earlier period, above the FactSet consensus of $694.9 million. The latest results reflect Endo's voluntary market withdrawal of the opioid pain medication Opana ER (notably, at the Food and Drug Administration's request), the company said, along with other factors like competitive pressures and discontinuations of U.S. generic drugs. Growth in the quarter, meanwhile, came from the company's launch of the antibiotic ertapenem for injection, an authorized generic for the brand-name of the antibiotic, Merck's Invanz, and continued growth in its U.S. brand-name sterile injectables products. Endo now expects 2018 revenue of $2.87 billion to $2.92 billion, above the FactSet consensus of $2.81 billion, and adjusted EPS from continuing operations of between $2.65 and $2.75, above the FactSet consensus of $2.60. Company shares have declined 1.2% over the last three months, compared with a 1.5% decline in the S&P 500 and a 2.3% rise in the Dow Jones Industrial Average .
DUBLIN , Nov. 8, 2018 /PRNewswire/ -- Third-quarter 2018 revenues of $745 million compared to third-quarter 2017 revenues of $787 million Third-quarter 2018 XIAFLEX ® franchise revenues increased 22 percent ...
On Thursday, Nov. 8, Endo (NASDAQ: ENDP ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue Endo EPS is ...
Endo's new drug candidate for treating cellulite showed "statistically signifiant" improvement in skin appearance in two phase-III clinical trials
Both RELEASE-1 and RELEASE-2 Studies Demonstrated Highly Statistically Significant Results (P=0.006 and P=0.002 respectively) on Efficacy Endpoints DUBLIN , Nov. 7, 2018 /PRNewswire/ -- Endo International ...
On BioSpecifics' (BSTC) Q3 conference call, investor focus will be on its progress with the development of CCH for treating uterine fibroids.